DrugIn clinical trials

Divarasib

divarasib

Investigational oral next-generation KRAS G12C inhibitor (Roche). Phase 3 Krascendo 1 (NEJM, 25 October 2026): in 338 patients with previously treated KRAS G12C-mutated advanced NSCLC, median PFS 9.8 vs 5.7 months (HR 0.58) and median OS 17.7 vs 12.0 months (HR 0.56) versus sotorasib or adagrasib. Not approved.

News about this drug

Also in the catalogue

Scales

Identifiers

INN
divarasib

Details

Status
In clinical trials
Class
KRAS G12C inhibitor

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.